Episode 11. ASH22 Recap: Lymphoma and CLL
Blood Cancer Talks
00:00
The Future of Autologous Transplants in Mental Cell Lymphoma
I think this trial should change practice and whether it will or not will depend on sort of regulatory and funding decisions outside of our control but I think you know this is the strongest data to date to show you that you can replace autologous with a Brutinib given in the way it was given. The D-Brutinib is actually relatively easy to prove that it's cost-effective here which might be a really kind of key key key point obviously the trial is relatively complex from a statistical point of view. We need to see early data with CLL, COVID-19 and B2K inhibitors subsequently after fixed duration maintenance so hopefully we'll get that from this study soon
Transcript
Play full episode
